ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
Quality of life for Fibromyalgia patients worsens after taking antidepressants for a year
Wednesday 11 September 2013
Editor's comment: This was a very small observational study. Just 18 patients completed the study and only seven of those were in the group taking antidepressants (five took an SNRI and two took an SSRI). However, the finding that these patients' quality of life worsened when taking antidepressants for a year is concerning – especially since two of the three drugs approved by the FDA for treating fibromyalgia are SNRI antidepressants. Additional larger studies are warranted.
Background: Antidepressant (AD) drugs are effective in the short term treatment of fibromyalgia (FM). It may be useful to study the long-term impact of AD on patients with FM.
Methods: One-year follow-up study on 23 females with FM divided into groups on AD (ADg-N=7), and not taking AD (NADg-N=11). Evaluation at t1 and at the end (t2) with the Fibromyalgia Impact Questionnaire (FIQ); at t2 with: SCID-IV; Mood Disorder Questionnaire (MDQ); Short Form-12; Hamilton Depression Rating Scale (HAM-D); Functioning Assessment Short Test (FAST)
Limitations: Observational research on few patients, not specifically designed to test the hypothesis. The results have a heuristic value only.
Discussion: The results should be read in the light of the high prevalence of patients screened positive for Bipolar Disorders and of the well-known poor response of the mood symptoms to antidepressants in Bipolar Depression. The deterioration in the long-term management of FM patients following AD treatments suggests the need for new and robust studies.
Source: Clinical Practice and Epidemiology in Mental Health, July 12, 2013. By M.G. Carta,, V. Ruggiero, F. Sancassiani, F. Cutrano, A.R. Manca, M. Peri, A. Fais, and E. Cacace. Dipartimento di Sanità Pubblica e Medicina Clinica e Sperimentale, Università di Cagliari e Center of Liaison Psychiatry and Psychosomatics, University Hospital of Cagliari, Italy.
The above originally appeared here.
blog comments powered by Disqus